P1.01-97 Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.653
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

JCSE01.09 Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-54 a Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Binimetinib Plus Gemcitabine and Cisplatin Phase I/Ii Trial in Patients With Advanced Biliary Cancers

Clinical Cancer Research
Cancer ResearchOncology
2019English

P1.01-04 Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Designing a Preliminary Adaptive Study to Inform a Biomarker Trial in Psoriasis

Trials
MedicinePharmacology
2011English

Behavioral Duality in an Integrated Agent

Frontiers in Human Neuroscience
Mental HealthNeuropsychologyPhysiological PsychologyNeurologyBehavioral NeurosciencePsychiatryBiological Psychiatry
2014English

Selection Bias in Cluster Trial

British Medical Journal
Medicine
2008English

Clinical and Biomarker Outcomes of the Phase II Vandetanib Study From the BATTLE Trial

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2013English

Single Ascending Dose Safety and Pharmacokinetics of CDRI-97/78: First-In-Human Study of a Novel Antimalarial Drug

Malaria Research and Treatment
EpidemiologyInfectious Diseases
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy